Seres Therapeutics (NASDAQ:MCRB) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note published on Friday, Benzinga reports. Canaccord Genuity Group currently has a $10.00 price objective on the biotechnology company’s stock.

Several other analysts have also recently commented on the company. Oppenheimer reiterated a market perform rating on shares of Seres Therapeutics in a report on Friday, June 7th. Chardan Capital reiterated a buy rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, August 14th. Finally, StockNews.com lowered shares of Seres Therapeutics from a hold rating to a sell rating in a report on Tuesday, August 13th.

Seres Therapeutics Stock Performance

Shares of NASDAQ MCRB opened at $1.02 on Friday. The firm has a 50 day moving average price of $1.03 and a two-hundred day moving average price of $0.91. The stock has a market cap of $154.48 million, a P/E ratio of -1.70 and a beta of 2.02. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $2.85.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period last year, the company earned $0.36 earnings per share. Analysts predict that Seres Therapeutics will post -0.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Seres Therapeutics news, insider Teresa L. Young sold 24,480 shares of Seres Therapeutics stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $1.08, for a total value of $26,438.40. Following the sale, the insider now owns 78,178 shares of the company’s stock, valued at $84,432.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 28,844 shares of company stock valued at $30,104. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Point72 DIFC Ltd bought a new position in shares of Seres Therapeutics in the second quarter worth $64,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Seres Therapeutics in the 2nd quarter valued at about $92,000. Providence Wealth Advisors LLC boosted its position in shares of Seres Therapeutics by 49.5% during the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 25,250 shares during the last quarter. Virtu Financial LLC purchased a new stake in Seres Therapeutics in the first quarter valued at approximately $73,000. Finally, Vanguard Group Inc. lifted its position in Seres Therapeutics by 12.1% during the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock valued at $5,213,000 after purchasing an additional 729,514 shares during the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.